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Abstract
Background: Lipopolysaccharide (LPS) is a gram-negative bacterial antigen that triggers a series of cellular
responses. LPS pre-conditioning was previously shown to improve the therapeutic efficacy of bone marrow stromal
cells/bone-marrow derived mesenchymal stem cells (BMSCs) for repairing ischemic, injured tissue.
Results: In this study, we systematically evaluated the effects of LPS treatment on genome-wide splicing pattern
changes in mouse BMSCs by comparing transcriptome sequencing data from control vs. LPS-treated samples,
revealing 197 exons whose BMSC splicing patterns were altered by LPS. Functional analysis of these alternatively
spliced genes demonstrated significant enrichment of phosphoproteins, zinc finger proteins, and proteins
undergoing acetylation. Additional bioinformatics analysis strongly suggest that LPS-induced alternatively spliced
exons could have major effects on protein functions by disrupting key protein functional domains, protein-protein
interactions, and post-translational modifications.
Conclusion: Although it is still to be determined whether such proteome modifications improve BMSC therapeutic
efficacy, our comprehensive splicing characterizations provide greater understanding of the intracellular
mechanisms that underlie the therapeutic potential of BMSCs.
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Background
Alternative splicing (AS) is important for gene regulation
and is a major source of proteome diversity in mammals
[1] through altering the composition of mRNA tran-
scripts by including or excluding specific exons [2]. AS
can further modulate organism complexity not only by
effectively increasing regulatory and signaling network
complexity, but also by doing so in a temporal- and
spatial-specific manner, supporting cell differentiation,
developmental pathways, and other processes associated
with multicellular organisms. Indeed, AS shows a strong
relationship with organism complexity, as estimated by
the organism’s number of different cell types [3]. The
recent ENCODE Project concluded that at least 90 % of
human genes express multiple mRNAs through alterna-
tive splicing of exons or exon segments [4]. As might be
expected, deregulation of this process is associated with
numerous diseases [5–10].
Bone marrow-derived mesenchymal stem cells (BMSCs)
are adult stem cells capable of self-renewal and differenti-
ation into numerous cell lineages, including osteocytes,
adipocytes, and chondrocytes [11]. One promising use of
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BMSCs is repair of ischemia-damaged cardiac tissue.
BMSCs are easy to expand in vitro, can be genetically
modified and exhibit significant immunotolerance proper-
ties [12–14], making BMSCs an attractive candidate for
tissue repair/regeneration therapy. Intramyocardial injec-
tion of BMSCs reduces inflammation, fibrosis, infarct size,
ventricular remodeling, and therefore, improves cardiac
function following tissue insult [15–18].
Because the majority of BMSCs are soon lost during
after injection, the observed therapeutic effects likely
derive from paracrine effects of bioactive molecules re-
leased from these cells [15, 16]. Indeed, BMSC-mediated
release of cytoprotective protein factors or transfer of
intracellular components (e.g.,mRNAs, microRNAs, and
proteins) via cell membrane exosomes, represents a
novel mechanism of cell-to-cell communication [19]. To
date, however, clinical trials have demonstrated that
while effective, delivery of BMSCs to ischemic myocardium
results in only modest and short-lived benefits [20, 21].
Therefore, there is a critical need to elucidate the mecha-
nisms by which BMSCs mediate their therapeutic bene-
fits, including identification of their specific paracrine
factor(s), and conditions under which their functions
can be optimized.
Upon injection into damaged heart tissue, BMSCs face
a hypoxic, ischemic environment that severely limits
their therapeutic efficacy. Thus, preconditioning BMSCs
with various growth factors and endogenous or exogen-
ous molecules has been used to improve BMSC thera-
peutic efficacy [22–24]. Indeed, it has been reported
previously that bacterial endotoxin (lipopolysaccharide,
LPS) could stimulate BMSCs to release paracrine factors,
including angiogenic growth factors, cytokines, and
chemokines that facilitate tissue repair [13, 14]. In
addition, our previous study suggested that BMSC
expression of the LPS receptor, toll-like receptor 4
(TLR4), regulates BMSC paracrine properties and intra-
cellular STAT3 signaling cascades [25]. Moreover, precon-
ditioning of BMSCs with LPS improves their therapeutic
efficacy in rodent models of ischemia/reperfusion injury
[23]. However, BMSC transcriptomic changes (in par-
ticular, alterations in mRNA transcript processing and
splicing) that occur following LPS stimulation have
been little studied.
Besides use as an attractive therapeutic tool for repair-
ing ischemic heart, BMSCs have been used for numer-
ous other diseases, including graft-versus-host disease,
Crohn’s disease, stroke, cartilage defects, diabetes and
many others [26–31]. With the growing incidence of
bacterial endotoxin LPS detected in older or immuno-
compromised patients with multiple-drug resistant bac-
teria, diabetes, cancer, indwelling IV catheters, and on
complex chemotherapy regimens [32, 33], it is of great
importance to study whether the stimulation of these
implanted BMSCs by endogenous LPS would alter their
therapeutic efficacy. Moreover, because MSCs are present
in bone marrow and many other tissues, it merits exten-
sive investigation whether LPS stimulation of these en-
dogenous MSCs would influence the clinical outcomes of
complex therapeutic regimens.
Despite BMSC’s strong clinical potential, the role(s) of
alternative splicing in LPS response has not been fully
explored. The recent development of high-throughput
sequencing technology has now made transcriptome-
wide profiling of splicing isoforms possible. In this study,
we used RNA-seq analysis of BMSCs to identify and
characterize gene transcripts whose splicing patterns
were altered by LPS treatment.
Results
To investigate LPS-induced transcriptomic changes in
BMSCs due to alternative splicing, RNA-seq analysis
was conducted on BMSCs before and after LPS treat-
ment, in triplicate. A strand-directed single-end RNA-
seq protocol (75 bp reads) was used with the SOLiD
5500xl instrument.
The total analysis resulted in 326 million reads, with
each of the six samples ranging from 43 to 59 million
reads. After removing the reads with low sequencing
quality (see Methods) and filtering reads mapped to
ribosomal RNAs and repeats, the remaining reads were
mapped to the standard mouse reference genome
(mm9). The total number of mappable reads in each
sample ranged from 29 to 36 million, with an average
mapping percentage of 59 %. Among the mappable reads
in each sample, 3.8 to 5.0 million are mapped to protein
coding exons, and 2.8 to 4.0 million are mapped to
splice junctions. Detailed mapping statistics for the six
samples are listed in Additional file 1.
LPS-induced alternative splicing
We applied a MISO (Mixture of Isoform) algorithm [34]
to identify alternative splicing events elicited by LPS
treatment. Based on a Bayesian inference framework,
MISO is a probabilistic framework that quantitates the
expression levels of alternatively spliced genes from
RNA-Seq data, and identifies differentially regulated
exons across samples. MISO computes Percent Spliced
In (PSI, or Ψ) values for each alternative splicing event,
representing the fraction of a gene’s mRNA that includes
the exon. For each event, MISO also calculates a Bayesian
Factor (BF) that quantifies the likelihood of the changes.
For instance, [BF] = 5 indicates it is five times more likely
that a specific alternative splicing event occurred than did
not occur.
Overall, we identified 197 exons whose splicing pat-
terns differed between control and LPS-treated BMSCs
(Bayesian factor [BF] > 5 and |ΔΨ| > 0.05). This number
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represents 2.32 % of all 8,475 events whose inclusion
percentages could be reliably measured from the RNA-
seq data; these genes generally had higher expression
levels to generate enough read depth for splicing ana-
lysis. For genes with lower expression levels, our RNA-
seq experiment did not have enough read depth for such
analysis. The 197 LPS-induced alternatively spliced
events included 82 cassette exons, 28 alternative donor
site events (5′-ss), 45 alternative acceptor site events
(3′-ss), and 42 intron retention events. Figure 1 demon-
strates the magnitude (X-axis) and significance (Y-axis)
of LPS-induced splicing pattern changes on all the alter-
natively exons that could be reliably identified by MISO
under both untreated and LPS-treated conditions (Fig. 1).
Among these 197 events (red dots in Fig. 1), 117 showed
positive ΔΨ values, indicating that the percentage of
transcripts containing the specific exon increased in the
LPS-treated samples compared to control samples. Simi-
larly, 80 events showed negative ΔΨ values, indicating a
decrease in the percentage of transcripts containing
specific exons. For each of the four types of splicing
events (cassette exons, alternative 5′-donor sites, alter-
native 3′-acceptor sites, and intron retention), we show
one Sashimi plot for the exons with the largest LPS-
induced changes (either increases or decreases) in per-
centage of inclusion in the gene product (Fig. 2). The
Sashimi plot demonstrates the RNA-seq read densities
along exons and junctions, in the context of the struc-
ture of the gene’s isoforms. In addition, the distribution
and the confidence intervals of the estimated Ψ under
both conditions (LPS vs. untreated) are also included.
To validate whether the alternative splicing events
were induced by LPS treatment, we performed RNA-seq
on BMSCs derived from MyD88−/− animals before and
after LPS treatment. MyD88 is a key signaling molecule
responsible for LPS response [35]. Among the 197 LPS-
induced alternative splicing events in wild-type BMSCs,
189 did not occur following LPS treatment of MyD88−/−
BMSCs (Fig. 3). This observation indicates that a large
majority of BMSC splicing changes were a direct conse-
quence of LPS induction, and such effects were negated
in cells whose LPS response is compromised. It should
be noted that in addition to MyD88 pathways, LPS also
functions through TRIF pathways [36]; the functions of
TRIF pathway is intact in the MyD88−/− cells. This
partially explains why some LPS-induced splicing effects
remained in MyD88-deficient animals.
Among the 197 LPS-induced alternative splicing events,
103 were located in the coding regions of transcripts, and
94 were either in the 5′- or 3′- untranslated regions
(UTRs). Among the 103 alternatively spliced coding
events, 65 were composed of multiples of three nucleo-
tides, leading to the inclusion or exclusion of specific
amino-acid residues in the final protein products. These
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Fig. 1 LPS-induced alternative splicing events. Scatter plot of all the AS events identified in MISO. The X-axis represents ΔΨ, and the Y-axis
represents log (BF). The shape of the dots indicates the type of the events. Specifically, circle indicates cassette exon events; star indicates
intron retention events; triangle indicates alternative 5′ splice site events; and diamond indicates alternative 3′ splice site events. Alternatively
spliced events with BF ≥ 5 are colored in red
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events could potentially generate multiple viable protein
products having the same translation frame. Thirty-eight
of the 103 coding exons contained either a premature stop
codon, and/or a shift in their translation frames. Such
events trigger either nonsense-mediated decay (NMD)
mechanisms [37], or a translated protein having a complete
different amino acid sequence downstream of the alterna-
tively spliced exon.
We then systematically examined the localization and
functions of the gene products possessing alternatively
spliced exons (Fig. 4 and Additional file 2). Among them,
64 were nuclear proteins, including 17 transcription
regulators, 13 enzymes, 2 kinases, 1 peptidase, and 1
ligand-dependent nuclear receptor. The 67 cytoplasmic
alternatively spliced gene products included 12 enzymes, 9
kinases, 6 transporters, 3 peptidases, and 2 translation
regulators. In addition, we also observed six potentially
secreted proteins and 18 plasma membrane-spanning
proteins. A detailed list of the genes in each category is
provided in Additional file 3. These results strongly
suggest that LPS induces splicing changes in highly diverse
proteins having a variety of cellular functions.
To understand the biological functions of genes whose
splicing patterns were altered by LPS treatment, we
conducted functional annotation analysis using the Dat-
abase for Annotation, Visualization and Integrated Dis-
covery (DAVID) v6.7 [38]. Three functional terms in the
SP_PIR (Swiss-Prot and Protein Information Resources)
category showed significant enrichment in our gene list.
Among the 161 genes that could be mapped to DA-
VID gene annotations, 97 categorized as phosphoproteins
(p-value = 7.2×10−12, FDR= 6.6×10−10). In addition, 26 genes
contained zinc finger domain proteins (p-value = 3.6×10−5,
FDR= 2.2×10−3) whose functions range from DNA or RNA
binding to protein-protein interactions and membrane asso-
ciation [39]. Furthermore, 35 genes were involved in protein
acetylation (p-value = 1.3 ×10−3, FDR= 3.2×10−2). Together,
these results suggest that LPS treatment has major effects
on the splicing patterns of signaling proteins.
Both gene expression levels and splicing patterns may
be altered by BMSC responses to LPS treatment. While
differential gene expression may lead to changes in the
abundance of the entire gene product, alternative spicing
modifies the structural composition of a specific protein.
Fig. 2 Sashimi plots of four types of AS events. Sashimi plots of four types of AS events were shown, including cassette exon, intron retention,
alternative 5′ and 3′ splice site. The red plots represent the LPS treated condition, and the blue ones represent controls. The X-axes indicate
genomic locations, and the Y-axes indicate transcription intensity. In each plot, a “sashimi-like” region indicates a heavily transcribed region, in
this case, exonic region. The blank regions between exonic regions indicate intronic regions. The “bridges” crossing exons indicate junction
reads. The numbers of junction reads are shown on the “bridges”. The exonic structure of each AS event is shown below each Sashimi plot.
On the right it displays the estimated Ψ (red line) value and the full posterior distribution (black bars)
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To evaluate to what extent the two mechanisms interact,
we examined the number of genes present in both dif-
ferentially expressed and alternatively spliced gene sets.
We utilized edgeR [40] to identify genes differentially
expressed between LPS-treated and control samples. In
total, 416 differentially expressed genes were identified
using a false discovery rate ≤ 0.05. Surprisingly, only one
gene, Plscr2 (Phospholipid Scramblase 2) was both differ-
entially expressed and alternatively spliced. The expression
level of Plscr2 increased 1.77-fold in LPS-induced samples
with FDR = 0.01, while the percentage of inclusion of one
cassette exon in the 3′-untranslated region (3′-UTR)
increased by 0.16.
Known protein domains are alternatively spliced in
LPS-induced transcripts
Alternatively spliced exons residing in known protein
domains are more likely to disrupt protein function.
Therefore, we systematically searched the overlap between
LPS-induced AS events for known protein family domains
documented in the pfam database [41]. Among 65 alterna-
tively spliced exons that did not disrupt codon frame,
seven overlapped with known protein domains (Table 1).
In addition, seven other known domains that overlapped
flanking exons had functions ranging from RNA and
protein binding, enzymatic activities, methyltransferase
activity, phosphopantetheinyl transferase activity, RNA
editing, and microRNA processing.
Alternative splicing in known protein domains may affect
protein-protein interactions
To examine whether alternatively spliced protein domains
modulate protein-protein interactions, we searched for
their binding partners based on two criteria: (1) at least one
experimental study supporting direct interaction between
the partner protein and the alternatively spliced protein in
-0.6
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Fig. 3 LPS-induced splicing changes in wild-type BMSC were repressed in MyD88−/− cells. The X-axis and Y-axis represents ΔPSI in wild type and
MyD88 knock out animals respectively. Blue diamond represents LPS induced AS events in wild type only, and red square represents LPS induced
AS events in both wild type and MyD88 knock-out cells
Nucleus
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Fig. 4 Distribution of AS genes in different cellular locations
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a known protein-protein interaction network [42, 43]; and
(2) at least one structural study in the Protein Data Bank
(PDB) supporting direct interaction between a domain in
the binding partner and the domain modified by alternative
splicing. For the first criterion, we merged two datasets of
experimentally validated direct interactions [42, 43] and
compiled a library of 9,795 protein-coding genes with
80,518 experimentally validated interactions. For the second
criterion, we derived the domain interactions in PDB from
iPfam [41] and then searched for proteins containing these
domains in Pfam [41]. In total, 3,573 interactions with
structural evidence were found between 13 alternatively
spliced coding transcripts and 3103 binding partners.
By joining two interaction tables, we identified eight
interactions having both experimental and structural
evidence. As shown in Fig. 5, these eight interactions
involved three genes with altered splicing domains,
Rabep1 (Rab GTPase-binding effector protein 1), Camk1d
(Calcium/Calmodulin-Dependent Protein Kinase 1D), and
Nr1h2 (nuclear receptor subfamily 1, group H, member 2).
The alternatively spliced exons in these genes overlapped
with known protein domains, including rabaptin, pkinase,
and ligand-binding domain of nuclear hormone receptor.
The differences in the percentage of inclusion for these
three events ranged from 14 to 31 %. The potential pro-
tein partners included Rabep1, Gga1 (Golgi-associated,
gamma adaptin ear containing, ARF-binding protein 1),
Gga2 (Golgi-associated, gamma adaptin ear containing,
ARF binding protein 2), Gga3 (Golgi-associated, gamma
adaptin ear containing, ARF binding protein 3), Camkk1
(calcium/calmodulin-dependent protein kinase kinase 1,
alpha), Nr0b2 (nuclear receptor subfamily 0, group B,
member 2), Rxra (retinoid X receptor, alpha), and Rxrb
(retinoid X receptor, beta). LPS-induced splicing changes
could significantly impact these proteins’ interactions with
their partners. Among these putative protein interaction
partners, only one protein, Nr0b2 (nuclear receptor sub-
family 0, group B, member 2), was not expressed.
Table 1 Alternatively spliced genes containing known protein domains
Gene Symbol AS Type Pfam Domain Domain Description
Ttc13 cassete exon TPR_11 TPR repeat
Rabep1 cassete exon Rabaptin Rabaptin
Camk1d cassete exon Pkinase Protein kinase domain
Nr1h2 alternative 5′ splice site Hormone_recep Ligand-binding domain of nuclear hormone receptor
Adarb1 alternative 5′ splice site A_deamin Adenosine-deaminase (editase) domain
Scoc alternative 3′ splice site DUF2205 Predicted coiled-coil protein
Ppip5k2 alternative 3′ splice site His_Phos_2 Histidine phosphatase superfamily (branch 2)
Rabaptin
Rabaptin
GAT
Gga1Rabep1
Rabep1
AS Genes AS Domains Interacting Domains Binding Partners
Gga2
Gga3
Camk1d Pkinase Pkinase Camkk1
Nr1h2 Hormone_recep Rxra
Rxrb
Nr0b2Hormone_recep
zf-C4
Fig. 5 PPI with both structural and experimental evidences. Ten AS gene products involved in protein-protein interactions. Gene symbols are
displayed in white regions, and corresponding protein domains are displayed with gray background. Blue line indicates a gene/protein contains a
domain, and a red line indicates an interaction between protein domains
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Intrinsic disorder and molecular recognition features in
LPS-induced alternative spliced regions
It was previously reported that alternatively spliced
regions are enriched with unfolded protein regions (in-
trinsic disorder) [44]. To examine these features within
LPS-induced alternatively spliced regions (cassette
exons, alternative 5’/3′ exons and retained introns), we
performed disorder prediction on the protein sequences
of these regions using VSL2B [45], a bioinformatics algo-
rithm for predicting intrinsically disordered regions
based on the biophysical properties of amino acids.
Among the alternative regions of 65 protein sequences
translated from LPS-induced alternative splicing
events, 34 (52.3 %) were predicted to be totally disor-
dered, 21 (32.3 %) partially disordered, and only 10
(15.3 %) totally structured (Fig. 6). These percentages
are consistent with previous reports that alternatively
spliced exons tend to locate in intrinsically disordered
regions [46].
A molecular recognition feature (MoRF) is a region
in an RNA that undergoes a disorder–order trans-
formation while bound by another protein. We pre-
dicted MoRF regions within the alternative regions
using the software tool MoRF2 [44]. As a result,
among the 55 alternatively spliced exons in the partial
or totally disordered regions, 22 contained regions
predicted to be MoRFs (Fig. 6, Additional file 4); these
regions could thus be regarded as potential protein-
protein interaction sites.
Post-translational modification sites within alternatively
spliced regions
We next annotated post-translational modification (PTM)
sites in regions affected by LPS-induced alternative
splicing. We searched known PTM sites deposited in
UniProt, and we also predicted novel ones using
ModPred [47]. Three alternatively spliced exons con-
taining known PTM (phorphorylation) sites localized to
three genes, Abi1 (abl-interactor 1), Depdc1a (DEP
Domain-Containing 1), and Ybx3 (Y box-binding pro-
tein 3). In addition, 13 PTMs were predicted to occur
in 29 alternatively spliced regions, including proteolytic
cleavage, phosphorylation, amidation, hydroxylation,
carboxylation, ADP-ribosylation, O-linked glycosyla-
tion, acetylation, GPI anchor amidation, palmitoylation,
pyrrolidone carboxylic acid, methylation and ubiquiti-
nation (Fig. 7). Proteolytic cleavage sites were the most
common PTM sites, appearing in 14 alternative re-
gions. It is possible that LPS affects the signaling activ-
ities of these proteins by inclusion or exclusion of the
PTM sites in the final protein product (i.e., whether or
not it is cleaved).
Totally Disordered
34
Partially Disordered
21
Structured
10
Without MoRF
12
With MoRF
9
Without MoRF
21
With MoRF
13
Arl13b
Arhgef11
Aif1l
Abi1
Ybx3
Cpeb4
Ncor1
Ctnnd1
Plec
Cdc42bpa
Nolc1
Rrbp1
Miip
Senp7
Tbc1d31
Depdc1a
Usp45
Rabep1
Ube2q2
Ambra1
Ehbp1l1
Zfp346
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b
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Fig. 6 Predicted disorder of AS gene products. a The distribution of 65 non-frameshifting protein coding AS genes in three categories, including
totally disordered, partially disordered and structured. b The MoRF containing and non-containing events among partially disordered AS genes.
The list of MoRF containing genes is shown on the right. c The same distribution and gene list as panel B but it is for totally disordered AS genes
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Characterization of potential splicing regulators
We defined 7 regulatory regions for each cassette exon
event (Fig. 8), among which Region 1 and 7 are 150 nt
constitute exon segments, Region 2, 3, 5 and 4 are
300 nt intronic segments, and Region 4 is the whole
cassette exon. We used FIMO [48] to search for CISBP-
RNA [49] motifs within the regulatory regions of both
up-regulated and down-regulated cassette exon events.
With p-value cutoff of 1E-4 and FDR cutoff of 0.1, we
identified 29 RBP motifs in the up-regulated events, and
23 in the down-regulated events. BRUNOL5, BRUNOL4
and RBM38 are the most frequently observed RBPs.
Their motifs concentrate in Region 2 and 3 for up-
regulated events, and in Region 5 for down-regulated
events. These three proteins are all known as RNA-splicing
related. Motifs of several other RNA-splicing related pro-
teins, including SRSF2, HNRNPL, HNRNPLL, HNRNPH2
and PCBP2, are observed in both up-regulated and down-
Fig. 7 Predicted PTM sites in AS regions. Column displays different types of PTM sites, and row displays the event types and LPS-induced AS
genes. The numbers in the shadowed grids on the crossing of gene A and PTM type B shows how many type B PTM sites fall in the AS region of
gene A. The total number of PTM sites in each gene is displayed on the right, and the total number of PTM sites in each type is displayed on
the top
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regulated cassette exon regulatory regions. Some RBPs
(SRSF9, RBM5, PCBP3, PCBP1, ZCRB1, NCL, FUSIP1,
PABPN1, TARDBP and NOVA2) are found exclusively in
up-regulated cassette exon events, and some (KHDRBS3,
BRUNOL6, G3BP2, FXR1, SRSF4, SNRNPA, SNRPB2) are
found exclusively in down-regulated events.
Discussion
Lipopolysaccharide (LPS, endotoxin) is a complex asso-
ciated with the outer membrane of Gram-negative bac-
teria, capable of triggering a series of cellular responses
in many cell types. One promising advance is to use LPS
as a pre-conditioning agent to improve BMSC therapeutic
efficacy for repairing ischemic, injured tissues [23, 50]. For
such application, because LPS is a potent stimulant for the
host immune system, BMSCs should be washed using
PBS to completely remove any residual endotoxin before
administration. We reported previously that BMSCs
treated with LPS produced more angiogenic factors VEGF,
IGF-1 and HGF [51, 52] which can spur the formation of
new blood vessels in ischemic tissue and survival and
differentiation of implanted BMSCs. By contrast, with the
growing incidence of sepsis, in which free LPS can bind to
and activate Toll-like receptor 4 on many cell types, the
roles of LPS on endogenous BMSCs and other cell types
are worth detailed investigation.
Microarray studies have reported that expression levels
of hundreds of genes can be altered after LPS treatment
in different tissues. In recent years, high-throughput
RNA sequencing technology has provided a more accur-
ate and comprehensive measurement of RNA transcript
levels and their isoforms than historic array-based
methods. This technological advance has enabled meas-
uring not only gene expression level alterations amongst
different conditions, but also complicated splicing pattern
changes in response to specific cellular perturbations. In
this study, we systematically identified alternative splicing
changes in mouse bone marrow-derived mesenchymal
stem cells (BMSCs) in response to LPS treatment, using
RNA-seq technology. We further implemented a series of
bioinformatics tools to evaluate the biological functions of
alternatively spliced exons and their host genes.
We observed strong enrichment in three functional
categories amongst the gene products whose splicing
patterns were altered by LPS treatment, phosphopro-
teins, zinc finger proteins, and proteins subject to acetyl-
ation. Most of these proteins were signaling proteins,
and the subtle differences in their splicing isoforms
could affect their function.
Among 161 gene products containing AS exons, 97
belonged to phosphoprotein families, five of which con-
tained documented phosphorylation sites in their AS
regions found in the UniProt database. These proteins
included Kansl2 (KAT8 regulatory NSL complex subunit
2), Depdc1a (DEP domain-containing 1), Abi1 (abl-inter-
actor 1), Ybx3 (Y box-binding protein 3), and UBl4a
Fig. 8 RNA binding protein (RBP) motifs in regulatory regions of differentially spliced events. RBP names and their occurrences are listed adjacent
to corresponding regulatory regions
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(Slc10a3-Ubl4 readthrough). The functions of these pro-
teins strongly associate with the functions of BMSCs.
For instance, Abi1 contains one cassette of exons whose
percentage of inclusion increased by 14 % after LPS
induction (ΔΨ = 0.14), with one phosphorylation site in
the AS region documented in the UniProt database.
Widely expressed with highest levels in bone marrow,
spleen, brain, testes, and embryonic brain, Abi1 may
negatively regulate cell growth and transformation by
interacting with the nonreceptor tyrosine kinases ABL1
and/or ABL2, thus regulating EGF-induced Erk pathway
activation and EGFR signaling. In addition to these five
proteins, eight other AS regions were predicted to have
phosphorylation sites, based on their amino acid contents.
These proteins included Usp45 (ubiquitin-specific pep-
tidase 45), Mark3 (MAP/microtubule affinity-regulating
kinase 3), Ncor1 (nuclear receptor corepressor 1), Ctnnd1
(cadherin-associated protein, beta 1), Ambra1 (autophagy/
beclin-1 regulator 1), Ddx6 (DEAD (Asp-Glu-Ala-Asp)
box helicase 6), Ehbp1l1 (EH domain binding protein 1-
like 1), and Akt1s1 (AKT1 substrate 1). Overall, LPS may
affect the functions of these proteins by including/exclud-
ing specific domains amenable to phosphorylation.
Among the proteins containing LPS-induced alterna-
tive splicing events, 25 contained multiple types of zinc
finger domains, including PHD (Plant Homeo Domain),
RING (Really Interesting New Gene), and C2H2-type
zinc-finger domains. Four proteins, Phf7 (PHD finger
protein 7), Phf20 (PHD finger protein 20), Phf20l1 (PHD
finger protein 20-like 1), and Phrf1 (PHD and ring finger
domains 1), contained PHD-type zinc finger domains
known to recognize trimethylated histone lysines (thus
possibly influencing chromatin structure). Four other
proteins, Rnf14 (ring finger protein 14), Rad18 (RAD18
homolog), Trim28 (tripartite motif-containing 28), and
Trim2 (tripartite motif-containing 2), all contain RING-
type zinc fingers, known ligases for ubiquitination en-
zymes and their substrates. It is well documented that
both PHD and RING-type domains are usually involved
in protein-protein binding [53, 54], and such binding
could possibly be disrupted by splicing variations.
Overall, the LPS-induced AS genes could be classified
into several categories (Fig. 9), including kinases, zinc-
finger proteins, transcription, RNA-binding, cytoskel-
eton, and protein acetylation. Many of these proteins
were also phosphoproteins, which play significant roles
in cell signaling. Analysis of the relationship between
splicing and protein structure has suggested that AS
exons play major roles in controlling protein-protein
interactions (PPIs) through disrupting either known pro-
tein interaction domains or molecular recognition sites,
which typically locate in intrinsically disordered regions.
Our analysis suggests that LPS-induced alternative splicing
could affect PPIs through both mechanisms. In particular,
protein interaction domains of three proteins with known
PPI partners were disrupted by LPS-induced splicing alter-
ations (Fig. 5). Interestingly, all three interactive domains
could self-interact (forming domain-domain interactions
with themselves), and one of these domains facilitates
homodimerization of Rabep1 (RAB GTPase binding ef-
fector protein 1). Expressed in embryonic tissues and most
types of stem cells, Rabep1 showed abundant expression in
BMSCs (about 30 RPKM). Homo-dimerization of this
protein is involved in early endosome fusion [55], an
event directly related to the paracrine effects of BMSCs,
where small vesicles are released when multivesicular
endosomes fuse with the plasma membrane [56, 57]. In
addition, Rabep1 also moderates intracellular transpor-
tation between lysosomes and the Golgi apparatus [58],
and between the Golgi apparatus and endoplasmic
reticulum [59]. LPS treatment also increased the inclu-
sion of the interaction domain by 14 %, which could in-
crease either homodimerization or heterodimerization
with other interaction partners.
We further evaluated how differences in splicing pat-
terns in transcriptional regulators affected their regulatory
activity by assessing gene expression changes of their
downstream target genes. NFYA (nuclear transcriptional
factor Y) contains an alternative acceptor site whose
splicing pattern in BMSCs is altered by LPS treatment; the
overall percentage of inclusion of the alternative acceptor
site decreased by 31 % (Sashimi plot for NFYA shown in
Additional file 5). Moreover, the expression of five down-
stream target genes of NFYA were enriched for genes
found differentially expressed (p-value ≤ 0.01) by LPS
treatment (FDR ≤ 0.05), including COL11A1 (collagen,
type XI, alpha 1), COL5A3 (collagen, type V, alpha 3),
FGFR2 (Fibroblast Growth Factor Receptor 2), PGK1
(phosphoglycerate kinase 1) and RGS4 (regulator of G-
protein signaling 4). It was previously reported that NFYA
activates transcription levels of COL11A1 and FGFR2
[60]; these two genes were both downregulated by LPS,
suggesting inhibition of NFYA function by the removal of
18 nt (or 6 amino acids) after LPS treatment, thus impact-
ing NFYA downstream effectors.
Conclusion
In summary, we used RNA sequencing to analyze
LPS-induced alternative splicing changes in BMSCs.
LPS modified the alternative splicing pattern of phos-
phoproteins, zinc finger proteins, and proteins subject
to acetylation. Most of the affected proteins were
signaling proteins that could change BMSC biological
function. Although it is still to be determined whether
such modifications underlie BMSC therapeutic ef-
ficacy, our characterizations provide greater under-
standing of the mechanisms and clinical usage of
promising BMSC therapies.
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Methods
Preparation of mouse BMSCs
A single-step stem cell purification method was employed
as previously described [61]. Briefly, BMSCs were col-
lected from the bilateral femurs and tibias of sacrificed
mice by removing the epiphyses and flushing the shaft
with complete media, Iscove’s Modified Dulbecco’s
Medium (IMDM; Life Technologies) and 10 % fetal bovine
serum (Life Technologies), using a syringe with a 26G
needle. Cells were disaggregated by vigorous pipetting and
passed through a 30-μm nylon mesh to remove any
remaining clumps of tissue. Cells were then centrifuged
for 5 min at 500 g at 24 °C. The cell pellet was then resus-
pended and cultured in 75 cm2 culture flasks in complete
media at 37 °C with 5 % CO2. Since BMSCs preferentially
attach to polystyrene [62], after 48 h, floating non-
adherent cells were discarded. Fresh complete media was
added and replaced every three or four days thereafter.
When the cells reached 90 % confluence, MSC cultures
were recovered by the addition of a solution of 0.25 %
trypsin-EDTA (Invitrogen) and passaged. Cell passage
was restricted to passages 6–10 for the experiments. To
purify BMSCs, the cells were subject to fluorescence-
activated cell sorting (FACS) analysis, with collection of
cells positive for Sca-1 and CD44 [62], but negative for
the hematopoietic stem cell and macrophage marker
CD45 [25].
RNA sample preparation and RNA-seq assay
BMSCs were plated at 1 × 105 cells/well/ml for 24 h and
further treated with LPS (200 ng/ml) for another 24 h,
and total RNA was extracted before and after LPS treat-
ment, following a standard protocol [25]. Experiments
were conducted in triplicate.
Standard methods were used for RNA-seq library con-
struction, EZBead preparation, and Next-Gen sequen-
cing, based on the Life Technologies SOLiD 5500xl
system. Briefly, 2 μg of total RNA per sample was used
Acetylation
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Transcription
Zinc-finger
RNA-binding
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Phosphoprotein
Fig. 9 Predicted interaction network among LPS-induced AS genes. Red nodes indicate genes producing phosphoproteins, and gray nodes
indicate genes not involved in protein phosphorylation. Genes associated with terms other than phosphoproteins are clustered in corresponding
shadowed areas. These terms include acetylation, cytoskeleton, transcription, zinc-finger, RNA-binding and kinase
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for library preparation. The rRNA was first depleted using
the standard protocol of RiboMinus Eukaryote Kit for
RNA-Seq (Ambion), and rRNA-depleted RNA was con-
centrated using a PureLink RNA Micro Kit (Invitrogen)
with 1 volume of lysis buffer and 2.5 volumes of 100 %
ethanol. After rRNA depletion, a whole transcriptome
library was prepared and barcoded per sample using
the standard protocol of SOLiD Total RNA-seq Kit
(Life Technologies). Each barcoded library was quanti-
fied by quantitative polymerase chain reaction (qPCR)
using SOLiD Library Taqman qPCR Module (Life Tech-
nologies) and pooled in equal molarity. EZBead prepar-
ation, bead library amplification, and bead enrichment
were then conducted using the Life Technologies EZ
Bead E80 System. Finally sequencing by ligation was
performed using a standard single-read, 5′-3′ strand-
specific sequencing procedure (75 nt-read) on SOLiD
5500xl.
Bioinformatics analysis for RNA-seq data
RNA-seq data analysis included the following steps: qual-
ity assessment, sequence alignment, and alternative spli-
cing analysis. The RNA-seq data can be accessed through
the Gene Expression Omnibus (http://www.ncbi.nlm.nih.-
gov/geo/) with accession number GSE64568).
Data processing and quality assessment
We used SOLiD Instrument Control Software and
SOLiD Experiment Tracking System software for read
quality recalibration. Each sequence read was scanned
for low-quality regions, and if a 5-base sliding window
had an average quality score less than 20, the read was
truncated at that position. Any read < 35 bases was
discarded. Our experience suggests that this strategy
effectively eliminates low-quality reads, while retaining
high-quality regions [63–65].
Sequence alignment
We used BFAST (http://sourceforge.net/projects/bfast/)
[66] as our primary alignment algorithm due to its high
sensitivity for aligning reads on loci containing small in-
sertions and deletions, as compared to the reference
genome (mm9). We then used a TopHat-like strategy
[67] to align the sequencing reads containing cross-
splicing junctions using NGSUtils (http://ngsutils.org/)
[63]. After aligning the reads to a filtering index includ-
ing repeats, ribosome RNA, and other sequences that
were not of interest, we conducted a sequence alignment
at three levels: genome, known junctions (University of
California Santa Cruz Genome Browser), and novel
junctions (based on the enriched regions identified
in the genomic alignment). We restricted our ana-
lysis to uniquely aligned sequences with no more
than two mismatches.
Alternative splicing analysis
We used MISO (mixture of isoforms) [34] to identify
alternatively spliced exons whose splicing patterns were
altered after LPS treatment. We first used Samtools
(v0.1.19) to merge six RNA-seq samples into two BAM
files according to their biological conditions, i.e., control
vs. LPS-treated samples. We then estimated Percent
Spliced In (PSI or Ψ), which indicates the proportion of
RNA isoforms containing the alternatively spliced exon
(inclusive isoforms) among all isoforms (inclusive plus
exclusive isoforms). We also computed a Bayes factor
(BF) to describe the likelihood of an AS event between
the LPS-treated and control conditions. A BF of 5 means
that an AS event is 5 times more likely to be differentially
spliced than not. Both Ψ and BF values were computed by
the software package MISO [34]. The difference between
Ψ s across the two conditions was defined as ΔΨ. We
required each AS event to have a BF > 5 and |ΔΨ| > 0.05
to be considered differentially spliced.
Ontological annotations
The functions and cellular locations of AS genes were
annotated by the pathway analysis tool Ingenuity Path-
way Analysis (IPA), and the functional and biochemical
properties of these genes were further annotated based
on SwissProt and PIR keywords with DAVID v6.7 [38].
Protein domains overlapping AS regions
Protein domain information was predicted based on the
RNA nucleotide sequences of the alternatively spliced
exon, and 30-base flanking sequencings of both up-
stream and downstream exons. These RNA sequences
were then translated into peptides, based on open read-
ing frames (ORFs) documented by Ensembl and Refseq,
which were then input into Pfam [41] for identification
of protein domains overlapping AS regions.
Identification of protein-protein interactions (PPI)
We also examined whether alternatively spliced exons
overlapped with potential protein-protein interaction
domains. Based on the protein domains identified in or
overlapping AS regions, we retrieved their binding part-
ner domains with iPfam [41], which documents domain-
domain interactions in the Protein Data Bank (PDB).
We further used Pfam to search for genes encoding part-
ner domains (i.e., potential protein interaction partners).
The identified protein interaction partners were verified
by two protein-protein interaction databases derived
from high-throughput experiments.
Other characterizations
Protein disorder was predicted with VSL2B [45], a highly
regarded protein disorder prediction tool, especially for
long regions of disorder [68]. We required the peptides
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flanking the AS regions to be at least 9 amino acids long
for accurate prediction. Potential binding sites were
predicted with MoRF2, a software tool that predicts
protein-binding sites that undergo a disorder–order
transformation while binding another protein molecule
[69]. Known post-translational modification (PTM) sites
were derived from UniProt, and novel PTM sites were
predicted by ModPred [47]. The upstream gene regula-
tor NFYA (Nuclear transcription Factor Y subunit
Alpha) [70] was predicted by Ingenuity Pathway Analysis
(IPA), based on gene expression data and known regula-
tory gene interactions.
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